We are live on ! Find out more
CTIC

CTI BioPharma Corp. (DE) Common Stock

Delisted

CTIC was delisted on the 23rd of June, 2023.

85 hedge funds and large institutions have $100M invested in CTI BioPharma Corp. (DE) Common Stock in 2014 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 26 increasing their positions, 22 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,433% more call options, than puts

Call options by funds: $1.89M | Put options by funds: $123K

18% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 22

4% less funds holding

Funds holding: 8985 (-4)

13% less capital invested

Capital invested by funds: $116M → $100M (-$15.4M)

25% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 16

Holders
85
Holders Change
-4
Holders Change %
-4.49%
% of All Funds
2.47%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
12
Increased
26
Reduced
22
Closed
16
Calls
$1.89M
Puts
$123K
Net Calls
+$1.76M
Net Calls Change
-$84K
Name Holding Trade Value Shares
Change
Change in
Stake
HCM
26
Highbridge Capital Management
New York
$311K +$334K +12,841 New
AQR Capital Management
27
AQR Capital Management
Connecticut
$289K
VOYA Investment Management
28
VOYA Investment Management
Georgia
$278K
MLICM
29
Metropolitan Life Insurance Company (MetLife)
New York
$268K +$157K +6,058 +121%
NFA
30
Nationwide Fund Advisors
Ohio
$251K +$2.08K +80 +0.8%
RhumbLine Advisers
31
RhumbLine Advisers
Massachusetts
$246K
VKH
32
Virtu KCG Holdings
New York
$235K +$102K +3,939 +68%
UBS AM
33
UBS AM
Illinois
$228K +$131K +5,020 +114%
AIG
34
American International Group
New York
$213K -$156 -6 -0.1%
BA
35
BlackRock Advisors
Delaware
$209K -$2.96K -114 -1%
CS
36
Credit Suisse
Switzerland
$186K -$252K -9,707 -56%
FHC
37
First Heartland Consultants
Missouri
$181K
DIA
38
Denver Investment Advisors
Colorado
$155K +$9.38K +361 +6%
ProShare Advisors
39
ProShare Advisors
Maryland
$129K -$31.4K -1,208 -18%
Morgan Stanley
40
Morgan Stanley
New York
$115K -$74.8K -2,878 -38%
Principal Financial Group
41
Principal Financial Group
Iowa
$108K
D.E. Shaw & Co
42
D.E. Shaw & Co
New York
$98K +$105K +4,031 New
EEG
43
E.E. Geduld
$97K -$26K -1,000 -20%
NCCM
44
Nine Chapters Capital Management
New Jersey
$77K -$20.8K -800 -20%
FNYS
45
First New York Securities
New York
$74K +$79.5K +3,056 New
AL
46
Airain Ltd
Guernsey
$68K +$73.1K +2,812 New
GC
47
Guggenheim Capital
Illinois
$67K -$106K -4,081 -60%
Legal & General Group
48
Legal & General Group
United Kingdom
$67K +$70.1K +2,698 New
Ameriprise
49
Ameriprise
Minnesota
$62K -$572 -22 -0.9%
PPA
50
Parametric Portfolio Associates
Washington
$62K +$66.3K +2,550 New

CTIC Hedge Fund Activity: Q3 2014 in Review

85 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q3 2014, worth a combined $100M — down 13% from $116M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of CTIC and 12 opened new positions — a net loss of 4 holders — while 22 trimmed existing stakes and 26 added.

The largest buyer was Eagle Asset Management, adding an estimated $2.26M. The largest seller was State Street, cutting an estimated $2.42M.

  • 85 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q3 2014, down from 89 in Q2 2014.
  • Funds reported $100M of CTI BioPharma Corp. (DE) Common Stock stock for Q3 2014, down 13% quarter-over-quarter.
  • 12 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q3 2014 and 16 closed out, a net change of -4 holders.
  • The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q3 2014 was Eagle Asset Management, an estimated $2.26M added.
  • The largest CTI BioPharma Corp. (DE) Common Stock seller in Q3 2014 was State Street, an estimated $2.42M sold.

Based on aggregated 13F filings for Q3 2014.